Retatrutide Dosage Protocol (5 mg Vial)

Two published study schedules translated into the selected vial's concentration. These are descriptions of monitored trial arms.

Phase 2 Trial Schedule (5 mg/mL)

Study frequency: Once weekly, subcutaneous, in the lower-start 12 mg arm of the phase 2 obesity study. Other groups had different targets and starting amounts. ^{[1] [2]}

Phase 3 Trial Schedule (5 mg/mL)

Study frequency: Once weekly, subcutaneous. The table follows the 12 mg target arm; separate groups ended at lower targets. ^{[3] [4]}

Reconstitution Steps

Rows above one vial or 100 U-100 units are flagged. The study material and clinical oversight are separate from this vial arithmetic.

Minimum arithmetic quantities for the illustrated 12 mg target-arm schedules over 12 and 24 weeks.

Vial totals use total nominal mass across the period. Water totals assume one modeled final volume per vial. Capacity equivalents sum the rounded-up 1 mL volume requirements per study week. *Swabs model two per capacity equivalent. These figures exclude losses and formulation-specific discard limits; they do not prescribe preparation or administration.

Actual Attest 30 mg vialModel: 5 mg nominal mass

U-100 scale100 units = 1 mL

Compatible diluentUse product documentation

Preparation suppliesFollow the governing procedure

Explore the nine-step preparation model. It tracks your selected vial mass and final volume, with feedback and a summary at the end.

ATTEST · PREPARATION MODELFull screen

Practice Reconstitution

Follow nine guided steps and review the model assumptions at the end.

30 mg product image
Model: 5 mg

Diluent

Scale

Start simulation

Educational model. Follow exact product documentation for a real vial.

ReadyReset

• Nominal vial mass: 5 mg total material in the model.
• Concentration: 5 mg ÷ 1 mL = 5 mg/mL.
• U-100 conversion: 50 mcg in 0.01 mL.
• Study frequency: The cited phase 2 and phase 3 arms used once-weekly administration. ^{[1] [3]}
• Vial coverage: Mass and volume calculations do not establish a storage period.

• Phase 2 obesity research evaluated placebo and 1, 4, 8 and 12 mg target groups. ^[1]
• TRIUMPH phase 3 programs evaluated 4, 9 and 12 mg targets across defined populations. ^[3]
• The chart displays selected 12 mg target arms, not every trial group.
• Changing vial strength changes concentration and measurement only. The historical study schedule stays fixed.

The phase 2 lower-start arm progressed through 2, 4, 8 and 12 mg; the phase 3 12 mg target arm progressed through 2, 4, 6, 9 and 12 mg, in four-week stages. ^{[1] [2] [4]}

These sequences describe study designs with eligibility criteria, investigated formulations and clinical monitoring. They are not selected by the calculator.

• Before preparation: Follow the exact vial's documented temperature, moisture and light requirements.
• After preparation: Use the documented storage conditions and discard period for that formulation and diluent.
• Label: Record concentration, preparation date and the supplied storage/discard instructions.
• Model limit: No general shelf life is inferred from vial size or arithmetic coverage.

Compare nominal vial yield and volume for the study amounts at the selected concentration.

1. Verify: Confirm total mass, exact formulation and the laboratory procedure.
2. Prepare: Gather the specified supplies and establish the documented clean preparation workflow.
3. Define volume: This illustration uses your entered final liquid volume. Check compatibility before any real preparation.
4. Mix and inspect: Follow the exact mixing and inspection requirements from the product documentation.
5. Label: Record the concentration and preparation/storage details.
6. Check arithmetic: Recompute the chart whenever vial mass or final volume changes.

Trial escalation is tied to assigned target groups and controlled monitoring. Phase 2 had multiple starting approaches, while the phase 3 sponsor describes planned four-week increments to assigned targets. ^{[1] [4]}

The two charts preserve those distinct designs. A 5 mg vial does not establish a 5 mg study target.

Retatrutide is being investigated as a single molecule acting at GIP, GLP-1 and glucagon receptors. The TRIUMPH program studies metabolic outcomes in defined populations. ^[3]

Receptor activity and vial concentration answer different questions: mechanism describes biological research, while this page's calculator describes nominal mass and volume.

The 48-week phase 2 obesity trial reported dose-related body-weight changes. The TRIUMPH design describes subsequent controlled studies across obesity and related conditions. ^{[1] [3]}

Read the original results and study methods for population, endpoints and uncertainty. This vial model does not predict an individual's outcome.

The phase 2 trial reported gastrointestinal adverse events and dose-dependent heart-rate changes. Trial findings belong to the investigated formulation and monitored participants. ^[1]

Retatrutide remains investigational. The arithmetic does not verify an Attest lot's identity, purity, sterility, stability or equivalence to trial material. ^[5]

• What volume does the default chart use? 1 mL final volume. Change the volume field to recalculate.
• What does one U-100 unit mean? 0.01 mL; peptide mass depends on concentration.
• Does vial strength change the study schedule? No. It changes nominal mass, concentration and yield.
• Why are some rows flagged? They exceed the nominal mass in one vial, the 100-unit scale, or both.
• Can the simulator validate a real preparation? No. It demonstrates a sequence and arithmetic assumptions.

This page models vial strength and measurement while describing published research schedules. It does not choose a dose, supply a clinical protocol or establish a storage period. Retatrutide is investigational.

1. 1NEJM: phase 2 obesity trialView source
2. 2ClinicalTrials.gov: NCT04881760 study armsView source
3. 3TRIUMPH registrational trial designView source
4. 4Lilly: phase 3 study escalation and targetsView source
5. 5Lilly: investigational Retatrutide contextView source